Physician

Mohammad Fahad Bin Asad, MD

According to 2025 Medicare claims, Mohammad Asad, MD (NPI: 1982910527) practices hematology/oncology in the Peoria, IL market, with the plurality of this provider's patient population coming from Peoria, IL. This provider's primary affiliated billing organization is ONCOLOGY-HEMATOLOGY ASSOCIATES OF CENTRAL ILLINOIS P C (NPI: 1801896063; TIN: 371331017) and primary practice location at 61615-7822. Asad is affiliated with the IRCCO (ACO ID: A2619) and OSF Healthcare System (ACO ID: A3289), participating under the MSSP model.

Asad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,007 traditional Medicare patients, billed 257,283 HCPCS/CPT codes, and received $3,754,266 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,962 prescription claims across 275 beneficiaries totaling $3,878,251 in drug costs, led by Revlimid (Lenalidomide). DME data shows 11 claims. Open Payments data shows 4 records totaling $61,349. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $167,074 to $3,754,266. Similarly, Part D prescription costs have risen steadily, from $26,303 to $3,878,251. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	459	1,974	$167,074
2016	514	2,201	$173,509
2017	339	1,374	$101,757
2018	31	37	$4,098
2019	21	27	$2,188
2020	12	12	$884
2021	99	2,553	$61,858
2022	842	164,138	$2,876,192
2023	986	220,441	$3,123,425
2024	1,007	257,283	$3,754,266

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	197	536	$26,303
2016	158	464	$20,544
2017	101	265	$89,738
2018	44	212	$764,705
2019	39	82	$110,915
2020	33	88	$243,404
2021	49	183	$319,573
2022	135	767	$679,301
2023	210	1,526	$2,500,796
2024	275	1,962	$3,878,251

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	11	$1,403

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	236	643	$93
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	202	459	$12
80053	Blood test, comprehensive group of blood chemicals	248	825	$10
36415	Insertion of needle into vein for collection of blood sample	247	857	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	268	1,026	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	78	2,156	$1,236,529
Lenalidomide	Lenalidomide	18	504	$325,553
Ibrance	Palbociclib	21	588	$314,927
Nubeqa	Darolutamide	18	540	$249,559
Xtandi	Enzalutamide	20	600	$220,186

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4150	Enteral formula, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	N	N/R	11	$1,403

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$16	CARDIVA MEDICAL, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$61,333	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohammad Fahad Bin Asad, MD?

Tedicare shows public-source Medicare data for Mohammad Fahad Bin Asad, MD (NPI 1982910527), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammad Fahad Bin Asad, MD have ACO affiliation data?

Mohammad Fahad Bin Asad, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619) and OSF Healthcare System (MSSP, ACO ID A3289).

What billing organization is linked to Mohammad Fahad Bin Asad, MD?

Mohammad Fahad Bin Asad, MD is linked to ONCOLOGY-HEMATOLOGY ASSOCIATES OF CENTRAL ILLINOIS P C (billing NPI 1801896063) in the available physician profile data.

Does Mohammad Fahad Bin Asad, MD have Open Payments data?

Mohammad Fahad Bin Asad, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.